华兰疫苗 (301207.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.2B	1.2B	1.1B	2.4B	1.8B
Cost of Revenue	271.3M	266.9M	212.6M	287.1M	217.5M
Gross Profit	933.7M	935.6M	915.3M	2.1B	1.6B
Operating Expenses
R&D Expense	150.0M	151.3M	162.6M	91.1M	134.6M
SG&A Expense	—	—	—	—	—
General & Admin Expense	49.3M	50.3M	81.2M	69.8M	95.7M
Selling & Marketing Expense	541.6M	544.5M	501.4M	949.0M	680.6M
Other Expenses	—	—	—	—	—
Total Operating Expenses	749.1M	754.6M	748.7M	1.1B	918.1M
Cost and Expenses	1.0B	1.0B	961.3M	1.4B	1.1B
Operating Income (EBIT)	193.8M	189.8M	214.9M	1.0B	592.6M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	192.9M	187.8M	214.5M	1.0B	589.5M
Income Tax Expense	5.4M	4.9M	9.0M	146.9M	69.8M
Bottom Line
Net Income	187.5M	182.9M	205.5M	860.0M	519.6M
Earnings from Cont. Ops	187.5M	182.9M	205.5M	860.0M	519.6M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	187.5M	182.9M	205.5M	860.0M	519.6M
Per Share
Basic EPS	CN¥0.32	CN¥0.31	CN¥0.34	CN¥1.43	CN¥0.88
Diluted EPS	CN¥0.32	CN¥0.31	CN¥0.34	CN¥1.43	CN¥0.88
Revenue Per Share	CN¥2.03	CN¥2.02	CN¥1.89	CN¥4.01	CN¥3.09
Shares
Basic Shares Outstanding	595.0M	595.1M	598.1M	600.7M	590.0M
Diluted Shares Outstanding	595.0M	595.1M	598.1M	600.7M	590.0M
Profitability Metrics
EBITDA	—	331.0M	356.9M	1.2B	733.2M
D&A	—	141.2M	142.1M	144.9M	140.6M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026